Diversified healthcare company CVS Health (NYSE:CVS) announced in Q1 CY2025, with sales up 7% year on year to $94.59 billion.

CVS Health sees strong Q1 2025 growth, but risks loom with downgraded revenue guidance and Medicare challenges. Read my ...

CVS Health has increased its full-year profit forecast and announced plans to exit the Obamacare health insurance market by ...

CVS Health hiked its 2025 forecast above Wall Street's expectations after improving Medicare benefits contributed to a better ...

CVS Health reported stronger-than-expected earnings and revenue for the first quarter Thursday, raising its full-year ...

CVS’s stock surges toward a one-year high after profit and revenue beat expectations, amid strength in the pharmacy business, ...

Shares of CVS Health Corporation (CVS) traded 10% higher in pre-market on Thursday after the company reported ...

CVS Health boosts its full-year profit expectations following robust quarterly results, indicating a rebound from last year's ...

The company now expects full-year adjusted earnings of $6 to $6.20 per share, up from a previous guidance of $5.75 to $6 per ...

The chart above depicts the trend in analyst earnings per share (EPS) forecasts for CVS Health Corp for the upcoming quarter. Analysts have not changed this quarter's expectations for EPS over the ...

Piero Cingari CVS Caremark To Place Novo Nordisk's Wegovy On Preferred Coverage For GLP-1 Weight Loss Treatment Wegovy to become preferred GLP-1 drug on CVS Caremark's top formularies in 2025 as ...

Sojitz, meanwhile, forecast net profit of 115 billion yen this fiscal year, up 4% from the previous year, after factoring in a 5 billion yen negative impact from the tariffs. "There will be a ...